Filing summary
Entity discrepancy: The request identifies LifeMD, Inc., but the supplied Form 10-Q is for Immudyne, Inc. This summary reflects the filing provided, not LifeMD.
Business context and reporting period
Immudyne develops, manufactures, and sells yeast beta-glucan immune-support products for oral and topical use, through healthcare professionals, distributors, and direct-to-consumer channels. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2015; it was signed August 13, 2015.
Financial results and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Sales | $277,353 in 2015; $196,611 in 2014, up 41% | $565,630 in 2015; $389,040 in 2014, up 45% |
| Gross profit / margin | $187,850 / 68%; $127,455 / 65% in 2014 | $401,911 / 71%; $270,794 / 70% in 2014 |
| Operating loss | $17,170, versus $75,377 in 2014 | $9,336, versus $253,015 in 2014 |
| Net loss | $21,028, versus $71,505 in 2014 | $19,362, versus $212,444 in 2014 |
- Six-month operating cash flow was negative $56,433, compared with positive $23,091 in 2014. Financing provided $60,486; cash increased $4,053 to $79,548.
- At June 30, current assets were $236,352 and current liabilities $412,673, yielding negative working capital of $176,321 and a current ratio of 0.6 to 1. Total liabilities were $417,273; notes payable were $98,486, including $40,200 owed to officers/directors and $58,286 to a commercial lender.
- Stockholders’ deficit was $165,660; accumulated deficit was approximately $8.5 million. Accounts receivable of $135,325 was entirely due from one customer.
Material changes and management commentary
- Management attributed sales growth to increased product demand. Gross margin improved modestly. Quarterly operating expenses were broadly stable; six-month expenses fell 21%, reflecting lower marketing, compensation, and litigation-related professional fees compared with 2014.
- The 2014 comparative six-month results included $25,000 of license-fee income and $7,877 of other income; the 2015 period had neither. Interest expense increased to $18,626 for the first half of 2015 from $906 in 2014, primarily related to the commercial loan.
- Management described plans to grow sales through strategic alliances, healthcare professionals, distributors, direct-to-consumer sales, and marketing. It expected marketing and public-company costs to weigh on future results. No quantified revenue or earnings guidance was provided.
- The company stated that additional capital would be needed to cover 2015 operating and capital requirements, while also saying its business and first-half borrowing were expected to fund operations through the remainder of 2015. Possible funding sources included increased sales, equity, debt, or support from officers/directors; availability and timing were not assured.
Risks, contingencies, and unusual items
- The filing states that accumulated losses and negative cash flows raise substantial doubt about the company’s ability to continue as a going concern. It warns that financing may not be available on acceptable terms; equity issuance could dilute shareholders and debt could add service obligations and restrictive covenants.
- Customer concentration is significant: one customer represented 83% of second-quarter sales and 83% of first-half sales, and 100% of accounts receivable at June 30. A second customer represented 12% of second-quarter and first-half sales.
- Disclosure controls and procedures were deemed ineffective. Identified material weaknesses included inadequate segregation of duties, insufficient written accounting/reporting procedures, inadequate computer-system access and disaster-recovery controls, and no written whistleblower policy.
- Accrued payables included $153,144 under a royalty agreement; the president has a 60% interest in royalties and has voluntarily deferred payments. The company reached the agreement’s maximum royalty-payment threshold during the second quarter. The Kentucky plant lease runs through May 2016, with $38,672 in disclosed remaining base rent.
- Management reported no known legal proceedings expected to have a material adverse effect and no material off-balance-sheet arrangements. Revenue-standard adoption was planned for fiscal 2018; the company was evaluating its impact.
Key facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Immudyne, Inc., not LifeMD, Inc.
- Assess the company’s ability to fund operations and meet obligations given negative working capital, low cash, going-concern uncertainty, and reliance on potential financing.
- Evaluate the concentration and collectability risk associated with the customer responsible for all receivables and most sales.
- Review remediation progress for the disclosed material weaknesses in disclosure controls.
- Verify loan repayment terms and the status of deferred royalty payments and related-party interests.